笃志创新 躬行致远:世界卫生组织《2023年全球结核病报告》结核病科学研究章节解读

doi:10.19982/j.issn.1000-6621.20240159

中国防痨杂志 ›› 2024, Vol. 46 ›› Issue (6): 613-617.doi: 10.19982/j.issn.1000-6621.20240159

笃志创新躬行致远:世界卫生组织《2023年全球结核病报告》结核病科学研究章节解读

舒薇, 刘宇红()

首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所/中国疾病预防控制中心结核病防治临床中心,北京 101149

收稿日期:2024-04-23 出版日期:2024-06-10 发布日期:2024-06-03
通信作者: 刘宇红,Email:liuyuhong0516@126.com
基金资助:
北京市卫生健康委员会高层次公共卫生技术人才建设项目(Discipline Leader 01-11)

Dedicating to innovation, practicing to achieve targets: interpretation of research & innovation part of the WHO Global Tuberculosis Report 2023

Shu Wei, Liu Yuhong()

Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute/Clinical Center on Tuberculosis, China CDC, Beijing 101149, China

Received:2024-04-23 Online:2024-06-10 Published:2024-06-03
Contact: Liu Yuhong, Email: liuyuhong0516@126.com
Supported by:
Beijing Municipal Health Commission High Level Public Health Talent Construction Project(Discipline Leader 01-11)

摘要/Abstract

摘要：

结核病领域创新性的研究与发展是终止结核病策略三大支柱之一,新技术和新策略是加速消除结核病进程的重要工具。2023年11月7日,世界卫生组织发布了《2023年全球结核病报告》,对全球结核病的流行情况,以及全球、区域和国家各级在预防、诊断和治疗结核病方面取得的进展进行更新。笔者就报告中结核病研究领域新诊断技术、新药与新方案及新疫苗等的研究及创新要点进行综述,并结合我国相关领域的研究进展进行分析,以期为我国结核病防治领域同行掌握结核病研究动态,进一步开展原创性研究和技术提供参考。

关键词: 结核, 研究, 总结性报告

Abstract:

“Intensified research and innovation” is the third pillar of the End TB Strategy, new research and technology are important tools to accelerate the process of eliminating tuberculosis (TB). On November 7, 2023, World Health Organization released the Global Tuberculosis Report 2023, updating the global prevalence of TB and the progress in the prevention, diagnosis and treatment. This paper reviews the key achievements in the areas of TB research and innovation for new diagnostics, drugs and regimens as well as vaccines introduced in the report, and discusses some of China’s indigenous progresses in related areas. This paper aims to make China’s TB professionals better informed about the latest research development in TB prevention and control around the globe, fostering indigenous TB innovation efforts with greater originality.

Key words: Tuberculosis, Research, Consensus development conference

中图分类号:

舒薇, 刘宇红. 笃志创新躬行致远:世界卫生组织《2023年全球结核病报告》结核病科学研究章节解读[J]. 中国防痨杂志, 2024, 46(6): 613-617. doi: 10.19982/j.issn.1000-6621.20240159

Shu Wei, Liu Yuhong. Dedicating to innovation, practicing to achieve targets: interpretation of research & innovation part of the WHO Global Tuberculosis Report 2023[J]. Chinese Journal of Antituberculosis, 2024, 46(6): 613-617. doi: 10.19982/j.issn.1000-6621.20240159

参考文献 18

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	World Health Organization. The Global Strategy for TB research and innovation. Geneva: World Health Organization, 2020.
[3]	World Health Organization. WHO TB Knowledge Sharing Platform. Geneva: World Health Organization, 2023.
[4]	United Nations. Resolution 73/3: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations, 2018.
[5]	Treatment Action Group. Tuberculosis research funding trends 2005—2021. New York: Treatment Action Group, 2022.
[6]	张立杰, 刘宇红. 联合国大会第二届结核病防治高级别会议政治宣言解读. 中国防痨杂志, 2023, 45(12): 1117-1119. doi:10.19982/j.issn.1000-6621.20230380.
[7]	General Assembly of the United Nations. Political Declaration of the High-Level Meeting on the Fight against Tuberculosis:draft resolution/submitted by the President of the General Assembly. New York: General Assembly of the United Nations, 2023.
[8]	World Health Organization. Use of targeted next-generation sequencing to detect drug-resistant tuberculosis Rapid communication, 2023. Geneva: Word Health Organization, 2023.
[9]	黄海荣. 世界卫生组织《应用新一代靶向测序技术检测耐药结核病:快速通告,2023》解读. 中国防痨杂志, 2023, 45(10): 921-924. doi:10.19982/j.issn.1000-6621.20230311.
[10]	Nyang’wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med, 2024, 12(2):117-128. doi:10.1016/S2213-2600(23)00389-2.
[11]	Guglielmetti L. End TB trial: Safety results in a study of five shortened, all-oral regimens for MDR/RR-TB. Int J Tuberc Lung Dis, 2023: S1.
[12]	Khan U. End TB trial: Efficacy results in a study of fiveall-oral, shortened regimens for MDR/RR-TB. Int J Tuberc Lung Dis, 2023: S1.
[13]	Goodall R. Long-term outcomes in STREAM Stage 2: A phase 3 trial in rifampicin-resistant TB. Int J Tuberc Lung Dis, 2023: S80.
[14]	Burhan E. Summary of the main TRUNCATE-TB trial results and outstanding questions. Int J Tuberc Lung Dis, 2023: S14.
[15]	Boeree MJ, Heinrich N, Aarnoutse RE. Treatment Strategy for Rifampin-Susceptible Tuberculosis. N Engl J Med, 2023, 388(24): 2297. doi:10.1056/NEJMc2304776.
[16]	Jindani A, Atwine D, Grint D, et al. Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis. NEJM Evid, 2023, 2(9): EVIDoa2300054. doi:10.1056/EVIDoa2300054.
[17]	World Health Organization. Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note. Geneva: Word Health Organization, 2023.
[18]	World Health Organization. Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note. Geneva: Word Health Organization, 2023.

笃志创新躬行致远:世界卫生组织《2023年全球结核病报告》结核病科学研究章节解读

Dedicating to innovation, practicing to achieve targets: interpretation of research & innovation part of the WHO Global Tuberculosis Report 2023

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 18

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	李敏, 姚宇珊, 乔海霞, 雷红. 肺结核与肠道菌群的相关性及治疗策略[J]. 中国防痨杂志, 2025, 47(4): 520-526.
[2]	李锦浩, 胡冬梅, 徐彩红. 结核病防治医务工作者开展预防性抗结核治疗工作意愿调查及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 398-407.
[3]	冯畏, 郑海伦, 孟炜丽, 罗萍. 2018—2023年北京市西城区结核病防治机构登记管理肺结核患者到位前漏报情况分析[J]. 中国防痨杂志, 2025, 47(4): 439-443.
[4]	郝明晓, 米洁, 许宗仪. 延续性护理路径在结核性脑膜炎患者中的应用效果分析[J]. 中国防痨杂志, 2025, 47(4): 477-481.
[5]	宋云林, 布祖克拉·阿布都艾尼, 王桂荣, 张继园, 鲁晓擘. 钙结合蛋白S100A12与中性粒细胞胞外诱捕网形成在重症肺结核患者肺损伤中作用机制研究进展[J]. 中国防痨杂志, 2025, 47(4): 513-519.
[6]	胡一凡, 杜博平, 吴亚东, 朱传智, 张蓝月, 贾红彦, 孙琦, 潘丽萍, 张宗德, 李自慧. Mce4C蛋白参与结核分枝杆菌摄取利用胆固醇的实验研究[J]. 中国防痨杂志, 2025, 47(4): 444-453.
[7]	盛杰, 洪凯峰, 米尔扎提·艾沙, 唐伟, 地里下提·阿不力孜. 白细胞介素22和p38 MAPK信号通路抑制骨关节结核骨质破坏的作用机制研究[J]. 中国防痨杂志, 2025, 47(4): 454-459.
[8]	尚希钰, 张慧芳, 曹玉清, 熊一白, 纪鑫毓, 田雅欣, 李佳佳, 王倪, 马艳. 基于文献计量学的结核病中医药基础研究全球研究现状及热点分析[J]. 中国防痨杂志, 2025, 47(4): 482-497.
[9]	秦丽莉, 杨澄清, 麦洪珍, 徐齐峰, 薛新颖, 路希维. 结核后肺曲霉病的临床诊疗研究进展[J]. 中国防痨杂志, 2025, 47(4): 498-504.
[10]	罗莉, 罗林紫, 尹曲华, 周磊, 卢志斌, 丁衍, 肖阳宝. 淋巴结瘘型气管支气管结核的支气管镜下诊疗进展[J]. 中国防痨杂志, 2025, 47(4): 505-512.
[11]	中国防痨协会结核病控制专业分会, 中国防痨协会青年分会, 《中国防痨杂志》编辑委员会. 中国结核病数字服药依从性技术应用指南[J]. 中国防痨杂志, 2025, 47(4): 385-397.
[12]	吴璇, 张艳秋, 徐吉英, 孟丹, 孙定勇. 2019—2023年河南省肺结核合并糖尿病患者治疗转归影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 425-431.
[13]	王颖超, 刘唯夷, 姬秀秀, 尚雪恬, 贾红彦, 张蓝月, 孙琦, 杜博平, 朱传智, 潘丽萍, 张宗德. 结核病患者外周血单个核细胞内环状RNA表达谱分析及诊断标识的鉴定[J]. 中国防痨杂志, 2025, 47(4): 460-470.
[14]	朱明智, 邵燕琴, 范大鹏, 刘立宾, 梅宾, 戴玲珊, 蔡龙. 尿液脂阿拉伯甘露聚糖抗原检测对肺外结核的诊断价值[J]. 中国防痨杂志, 2025, 47(4): 471-476.
[15]	黄伟强, 袁楚楚, 陈星星, 商会会, 徐雅, 胡明. 康替唑胺替代利奈唑胺方案治疗耐药结核病一例[J]. 中国防痨杂志, 2025, 47(4): 527-530.

笃志创新 躬行致远:世界卫生组织《2023年全球结核病报告》结核病科学研究章节解读

Dedicating to innovation, practicing to achieve targets: interpretation of research & innovation part of the WHO Global Tuberculosis Report 2023

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 18

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

笃志创新躬行致远:世界卫生组织《2023年全球结核病报告》结核病科学研究章节解读